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Cerebral dehydration action of glycerol 
I. Historical aspects with emphasis on the toxicity and 
intravenous administration 
Oral glycerol (1 Gm. per kilogram every 6 hours) has a dehydration effect on the central 
nervous system. Prolonged continuous administration of glycerol does not produce marked 
alteration of fluid and electrolytes. It is almost totally excluded from the brain, which excludes 
the problem of rebound overhydration. It has significant nutritional value nad none of the 
side effects of steroids. The maior toxic effects of glycerol (hemolysis, hemoglobinuria, and 
renal failure) can be prevented and are a function of concentration and route of administration. 
Glycerol does not hemolyze red blood cells when it is prepared with isotonic saline in 
concentrations up to 40 per cent. Human intravenous glycerol has been used safely on a 
number of occasions with plasma levels reaching 10 mmoles per liter to measure turnover 
rates in adults and infants. The same oral glycerol dose is effective in lowering ocular tension 
and cerebrospinal fluid pressure. The plasma concentration response curve for normal human 
eyes has been previously determined. Intraocular pressure begins to fall when plasma glycerol 
is approximately 10 mmoles per liter. It is proposed that continuous intravenous glycerol be 
considered for treatment of cerebral edema in patients not able to take oral glycerol. 
Wallace W. Tourtellotte, M.D., Ph.D., James L. Reinglass, M.D., and 
Tracy A. Newkirk, M.D. Ann Arbor, Mich. 
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Animal and human dehydration action 
Virno and associates, 78 in 1961, first 
described the action of oral and intra-
venous glycerol in reducing experimentally 
induced cerebral edema in rabbits. Expan-
sion and contraction of the exposed cere-
bral cortex was measured by a pointing de-
vice mounted on the surface of the brain. 
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In a later study,76 glycerol was given by 
gastric tube to rabbits with intraocular 
hypertension induced by means of water 
intoxication. The intraocular hypotensive-
acting glycerol lasted for about 6 hours 
and the effective dose proved to be very 
similar to the most effective dose to pro-
duce cerebral dehydration. Mandell and 
associates44 used 4 Gm. per kilogram of 
glycerol for the treatment of cerebral 
edema in rabbits induced by triethyltin sul-
fate. Within one hour, brain water 
fell by 9.5 per cent and brain sodium 
159 
160 Tourtellotte, Reinglass, and Newkirk 
by 15 per cent. At 6 hours, brain water 
returned to pretreatment values, whereas 
sodium levels were almost normal. They 
did not demonstrate an over-rehydration 
of the brain after discontinuing glycerol. 
In 1963, Cantore and associates14 re-
ported the use of oral glycerol for the 
reduction of cerebral edema in animals and 
man. In 1965, they15 reported its effect on 
a much larger series of patients: 62 pa-
tients had a space occupying lesion, 75 
patients were observed during neuro-
surgery, 84 were postoperative patients, 
and a "limited number" had pseudotumor 
cerebri. They reported excellent results with 
no associated rebound overshoot or toxicity 
other than gastric irritability predisposing 
to nausea and vomiting. More important, 
however, was their observation that no 
additional electrolytes were needed with 
patients treated with glycerol for extended 
periods of time. In comatose patients, ap-
propriate amounts of water and electrolytes 
were given without interfering with anti-
edema effect. The diuresis following ad-
ministration of glycerol was not great. A 
single dose ranged from 0.5 to 2.0 Gm. per 
kilogram, and in some cases they gave 5 
Gm. per kilogram per day in 8 divided 
doses. Bovet and associates" pointed out 
that although glycerol promoted diuresis, 
its action of reducing cerebral edema was 
not dependent on diuresis. Along this same 
line, it has been reported that glycerol is 
effective for control of intracranial hyper-
tension even in nephrectomized animals. 
Buckell and Walsh11 described the use of 
oral glycerol in 2 patients with benign intra-
cranial hypertension. Pure glycerol, 75 ml., 
produced about 30 to 40 per cent less 
diuresis than did a similar dose of urea. 
They also did not find rebound rehydration 
of the brain. Following the publications of 
Bovet and associates and Buckell and 
associates, numerous reports3• 16- 18• 20• 23 • 30• 
33, 4o, 45, 46, 5o, 58, 10, n, 11 of oral glycerol ap-
peared in the literature describing its ac-
tion on the reduction of intraocular pres-
sure but only a few on central nervous 
system ( CNS) dehydration. 
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Plasma glycerol levels necessary for re-
ducing intraocular pressure have been 
studied by McCurdy and associates.45 Eight 
normal human volunteers were given a 50 
per cent solution of lemon-flavored glycerol 
in doses of 1.0 to 1.27 Gm. per kilogram 
after an overnight dehydration of 12 to 14 
hours. Plasma and urine glycerol levels 
were measured by the glycerolkinase enzy-
matic method of Wieland. 81 Blood glycerol 
determinations revealed an average fasting 
control value of 0.51 mmoles per liter ( 4.6 
mg. per 100 ml.). After glycerol ingestion, 
blood levels rose to a maximum of 20 
mmoles per liter in 60 to 90 minutes. 
Plasma osmolality rose an average of 19 
mOsm. per kilogram of water. There was 
a tendency for osmolality to remain elevated 
even after ocular tension began to return 
to normal. Glycerol excretion revealed that 
only 7.5 to 13.9 per cent of the total glycerol 
appeared in urine during the 2¥2 hour 
period of study. Intraocular pressure fell in 
all 8 normal subjects within 7 to 12 minutes 
after ingestion. Accordingly, they showed 
that plasma glycerol and osmolality varied 
inversely with the ocular tension. Maximal 
ocular hypotension occurred at 50 to 90 
minutes. Ocular pressure began to fall at 
plasma glycerol levels of approximately 10 
mmoles per liter. Blood volume was not 
measured directly, but hematocrit levels 
fell an average of 4.8 per cent with the 
lowest value 80 minutes after ingestion. No 
hemolysis was noted, and all hematocrit 
values returned "toward control values by 
the end of the study." Serum sodium fell 
an average of 4.5 per cent during the same 
period. Blood glucose levels remained con-
stant in the 4 subjects in whom it was mea-
sured. 
Absolon1 has reported on a patient with 
benign intracranial hypertension treated 
with oral glycerol for 22 days in the hos-
pital and 18 weeks as an outpatient. Glyc-
erol was effective in controlling the papil-
ledema; the only side effect noted was 
nausea. When glycerol was stopped, the 
papilledema returned. Glycerol was not 
given again. 
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Fig. I. Effect of a test dose of 50 per cent glycerol in 0.9 per cent sodium chloride, 1 ml. 
per kilogram ( 90 ml.), by nasogastric tube, on CSF pressure in a patient (Case 1) with 
benign intracranial hypertension. 
The only other references we have knowl-
edge of in regard to the CNS dehydration ef-
fect of glycerol are our own studies. Newkirk 
and associates"' treated a patient in coma 
with intracranial hypertension secondary to 
Echo III encephalitis with oral glycerol ( 1 
mi. per kilogram every 6 hours ) for 21 
days; there was a favorable outcome. De-
spite a fluid intake of 3,000 mi. per day, 
normal serum, potassium, chloride, and 
C02 values were maintained. Two addi-
tional patients ( Cases 1 and 2) with benign 
intracranial hypertension were given oral 
glycerol tests. 
Case 1. A 15-year-old obese boy was treated 
with antibiotics for otitis media. Two days later 
he developed diplopia, nausea, vomiting, and a 
headache. On the twelfth day of illness, the 
diplopia was much worse. On the thirty-fifth day, 
the CSF pressure was 370 mm. of CSF. He had 
a normal Tobey-Ayer test, skull roentgenogram, 
brain scan, and arteriogram. On the forty-fifth 
day, he was given a test dose of glycerol with 
the results shown in Fig. 1. He was then placed 
on glycerol, 1 ml. per kilogram, orally, every 6 
"Newkirk T. A., Tourtellotte, W. W., and Reinglass, 
J. L.: Prolonged control of increased intracranial pressure 
by glycerol, Arch Neurol. In press. 
hours. By the fiftieth day, he was symptom 
free. 
Case 2. A 38-year-old woman presented with 
headaches and visual complaints ("wavy lines" 
and "black spots"). On the twenty-first day of 
illness, bilateral papilledema with mildly en-
larged blind spots were found. Normal arterio-
gram and pneumonencephalogram were obtained. 
The CSF pressure was 400 mm. On the forty-
eighth day, a glycerol test was done. The results 
are shown in Fig. 2. Glycerol was discontinued 
because of nausea and vomiting, so she was 
treated with dexamethasone, 1.5 mg. three times 
daily. With this treatment, CSF pressures ranged 
from 120 to 180 mm. 
The plots of the cerebrospinal fluid 
( CSF) pressure versus time in minutes of 
these 2 patients are shown in Figs. 1 and 2, 
respectively. These graphs are virtually 
identical to those presented by Buckell and 
Walsh11 for the CNS and are similar to 
those presented by McCurdy and associ-
ates45 for the eye. 
We are not aware of any specific or 
potential problems directly related to the 
anticerebral edema action of glycerol, such 
as increased cerebral blood flow or sub-
dural hemorrhage extension, as have been 
reported with urea.8 
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Fig. 2. Effect of a test dose of glycerol, 3 ml. per kilogram ( 180 ml.) by nasogastric tube on 
CSF in a patient (Case 2) with benign intracranial hypertension. 
Toxicity 
Glycerol is constantly metabolized by the 
body, hence it would seem safe to conclude 
a priori that within a certain range it is 
innocuous. It would seem that this is the 
case, since a 21h-year-old child survived 
without any obvious sequelae after the acci-
dental ingestion of 23 Gm. per kilogram. 21 
Nevertheless numerous misconceptions 
exist about the toxicity of glycerol, most 
of which resulted from poorly controlled 
studies which did not delineate dosage, 
route of administration, or concentration. 
In 1876 Ustimowitsch72 reported that 
given by the intravenous route glycerol 
gave rise to hemoglobinuria and albumin-
uria. Simon,63 in 1915, reported hemolysis 
and Piras52 in 1925, found abnormalities in 
the kidney, liver, and intestines. These in-
vestigators either used undiluted glycerol 
or did not report the concentration or dose. 
Contrarily, Amschink, 2 in 1887, and Leo41 
and Niclous, 48 in 1903, did not report the 
occurrence of hemoglobinuria after oral 
glycerol. 
However, it remained for Johnson and 
co-workers, 35 in 1933, to dispel some of the 
previously reported conclusions. They 
studied rats, dogs, and man in an effort to 
further understand the toxicity and phar-
macologic parameters of glycerol. Rats were 
divided into 4 groups and fed a diet which 
contained 20, 40, or 60 per cent glycerol 
for nearly a year. Growth, weights, and 
number of weaned offspring did not vary 
from those of controls. All rats were put to 
death and postmortem examinations were 
made on kidney, liver, and intestines. No 
abnormalities were found. Dogs given diets 
which contained 35 per cent glycerol for 
50 weeks showed similar growth curves to 
the control group. Erythrocyte counts did 
not change. No albuminuria was found. 
Three dogs given 9.0 Gm. per kilogram 
per day for one year showed no ill effects. 
Microscopic studies of lung, kidney, liver, 
and spleen showed no abnormalities. But 
3 Gm. per kilogram given intraperitoneally 
produced hemoglobinuria, and a similar 
dose given subcutaneously also produced 
albuminuria and hemoglobinuria. 
In this same study observations were 
made on 14 college students given 30 mi. 
of glycerol ( 1.3 to 2.2 Gm. per kilogram) 
in orange juice with each meal for 50 days. 
The subjects were observed for changes in 
weight, erythrocyte and leucocyte counts, 
and hemoglobinuria. No pathologic find-
ings were noted. Because Rosenfeld57 and 
Lewis and Corley42 reported elevated uri-
nary excretion of uric acid, Johnson and 
associates also studied this aspect. Using a 
dietary control, they were able to confirm 
that basal metabolic rates and temperatures 
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in these students were not changed sig-
nificantly. Therefore, Johnson and associates 
concluded that oral glycerol was exceed-
ingly safe in man. 
A number of reports of the toxic effects 
of glycerol appeared in the literature fol-
lowing the comprehensive study of Johnson 
and associates. Sugimoto68 noted anemia 
in rabbits treated subcutaneously with 3 ml. 
per kilogram of glycerol. Maignon and 
Grandclaude43 reported venous sclerosis in 
dogs following injection of 3.5 ml. of glyc-
erol. Pfeiffer and Amove51 noted that 0.75 
mi. per kilogram of glycerol was the lowest 
subcutaneous dose capable of producing 
hemoglobinuria in rats. They also reported 
that ascorbic acid provided protection. In 
a review of glycerol in 1940, Deichmann21 
concluded that the quantity necessary to 
produce toxicity varied with the mode of 
administration-the dose needed with the 
intraperitoneal route was the lowest, that 
with the subcutaneous, intermediate. The 
oral route was nontoxic. Furthermore, 
Miner and Dalton47 noted that albuminuria, 
hemoglobinuria, and anemia had never 
been reported as a result of taking glycerol 
orally. 
In 1956, Cameron and Finckh12 finally 
settled the question of hemolysis and hemo-
globinuria as a function of concentration 
and route of administration. In the rat, sub-
cutaneous concentration of 5 to 50 per cent 
glycerol resulted in hemoglobinuria, the 
severity of which varied with the total dose. 
The smallest amount capable of producing 
hemoglobinuria was 0.2 ml. of undiluted 
glycerol per kilogram. Experiments with 
the intravenous injection of glycerol in rats 
revealed that 50 per cent solutions always 
produced hemolysis and in large doses led 
to convulsions. However, injection of 20 
per cent glycerol could be given rapidly 
intravenously in amounts up to 20 mi. per 
kilogram without producing hemoglobi-
nuria or hemolysis. Such a dose represents 
20 times that shown to produce these effects 
by the subcutaneous route. 
These results were confirmed by Zilver-
smit and associates.87 They gave 10 per 
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cent glycerol intravenously in a dose of 4.8 
Gm. per kilogram as a daily dose and 
found no ill effects in dogs. They stated 
that there are no reports of hemoglobi-
nuria, hemolysis, or renal damage from 
intravenous infusion of 20 per cent glycerol 
or less when the diluent was isotonic so-
dium chloride. The reason why the sub-
cutaneous and intraperitoneal routes are 
20 times more toxic than the intravenous 
route is not known. 
Finckh24 found that intraperitoneal glyc-
erol was as capable as subcutaneous glyc-
erol in producing renal damage, and both 
did so in the absence of hemolysis. Finckh 
also showed that glycerol itself was not 
directly toxic to the tubular epithelium. To 
deepen the mystery, Finckh observed that 
excision of the subcutaneous tissue with its 
surrounding zone of edema prevented the 
renal damage, provided that it was done 
within 2 hours after injection. These find-
ings suggest that either subcutaneous or 
intraperitoneal injections of glycerol are 
capable of producing or releasing a com-
pound which damages the kidneys. Such a 
compound has not been isolated. 
Along this same line, Wilson and asso-
ciates84 and Oken and co-workers49 per-
formed micropuncture studies of individual 
rat nephrons damaged by glycerol admin-
istered subcutaneously. Renal failure was 
manifested by a greatly decreased proximal 
tubular fluid flow rate that persisted long 
after peritubular circulation seemingly re-
turned to normal. Also, combined mannitol 
and isotonic sodium chloride were capable 
of preventing renal damage induced by 10 
mi. per kilogram of 50 per cent glycerol 
injected subcutaneously. 
Finally, the histopathologic changes in 
the kidneys resemble acute tubular necrosis 
and have been described by Bondi and 
associates6 and Della Rocca and co-work-
ers.22 The latter studied histologic prepara-
tions of the kidneys of rabbits following the 
intravenous administration of 2.0 Gm. per 
kilogram of 30 per cent glycerol. They 
described vasoconstriction of the afferent 
glomerular arterioles. This change, they felt, 
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was responsible for the hematuria and 
could be prevented by the addition of 
sodium ascorbate to the glycerol. 
The fact that glycerol does not have a 
direct toxic effect on erythrocytes was 
shown by Smith67 who described the first 
use of glycerol for the prevention of hemol-
ysis during freezing and thawing. Noting 
that glycerol had previously been used to 
preserve the viability of sperm, viruses, and 
sarcoma cells, she diluted samples of blood, 
1:1, with equal volumes of 30 per cent 
glycerol in Ringer's solution. The samples 
were then frozen at -79° C. No hemolysis 
appeared up to 8 weeks. Further studies 
showed that essentially the same results 
could be obtained with glycerol concentra-
tions between 10 and 20 per cent and with 
isotonic saline as the diluent. These findings 
appear to contradict earlier reports 32 in 
which in vitro hemolysis could be produced 
by low concentrations, such as 3 per cent. 
Simon63 recognized that a 1.0 per cent 
solution of sodium chloride protected eryth-
rocytes against hemolysis by glycerol. Along 
this same line, Johnson and associates35 
pointed out that aqueous solutions of glyc-
erol cause hemolysis, probably on the same 
basis as distilled water does, but that a 
solution of glycerol in isotonic saline was 
not hemolytic. Schiibel59 studied isotonic 
saline-washed erythrocytes to which vari-
ous concentrations of glycerol were added. 
He found no hemolysis in saline solutions 
containing up to 40 per cent glycerol, while 
in 50 per cent solutions, 20 to 50 per cent 
glycerol caused hemolysis after several 
minutes. Similar results were obtained with 
urea. Urea in water is hemolytic, but when 
the diluent was isotonic saline very high 
concentrations of urea were found not to 
be hemolytic. They explained hemolysis by 
glycerol as follows: An excess of water 
enters the cell to such an extent that the 
cell membrane is disrupted by stretching; 
it does not disintegrate the cell membrane 
per se, as does saponin. It would appear 
that glycerol (or urea) which diffuses 
freely into the cell is the driving force, 
hence, the osmolality of the intracellular 
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space is increased. Accordingly, a greater 
amount of water enters the cell by osmosis 
which can result in hemolysis if the swelling 
is excessive. It is an expected result that 
the addition of a solute to the extracellular 
space which does not readily pass the mem-
brane, such as sodium chloride, would de-
crease the osmotic movement of water into 
a glycerolized erythrocyte. It turns out that 
hemolysis can be prevented or decreased 
by a salineous solute over a large range of 
concentrations even if the concentration of 
glycerol is 50 per cent. 
Following the reports by Smith, pre-
quick freeze glycerol treatment of eryth-
rocytes to prevent ice artifacts became a 
common practice. In the method of Hug-
gins,31 for example, a final concentration of 
glycerol of 5.6M (52 per cent) is used. 
Although reports of hemolysis have been 
found with this method, they have been 
shown to be caused by slow freezing and 
thawing technique with the subsequent 
formation of ice crystals53 or to suspension 
of the erythrocytes in a "artificial" protein 
solution. 73 It is estimated that as much as 
5 Gm. of glycerol per 100 ml. is given at 
the time of transfusion, even though the 
erythrocytes have been washed in the ac-
cepted fashion. 64 
To our knowledge, no adverse side ef-
fects which are permanently disabling have 
been produced by oral glycerol. 
Nausea and vomiting induced by the 
sweet taste of glycerol can be a problem 
severe enough to require discontinuation of 
the therapy. Johnson and associates,35 after 
some experimentation on their graduate stu-
dents, disguised the sweet taste of glycerol 
with orange juice. A layer of orange juice 
was floated on about 35 mi. of glycerol. Im-
mediately following the rapid drinking of 
this, leaving about 5 mi. of the viscous 
material clinging to the sides of the 
tumbler, a swallow of orange juice from 
another glass was taken. Thus, they gave 
orange juice immediately preceding and 
following the glycerol and there was little 
to be tasted except the orange juice. Jaffe 
and LighP3 had patients sip, through a 
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soda straw, 150 mi. of a 50 per cent v /v 
solution of glycerin in a pleasant lime-fla-
vored aqueous vehicle in cracked ice. Ap-
proximately 5 per cent of them still vom-
ited. Cantore and associates15 attenuated 
the sweetish taste of glycerol by diluting it 
50 per cent in 0.9 per cent saline. Lemon 
juice was added and the mixture was 
chilled. They also noted that ingestion of a 
small amount of food helped. Parenteral 
injection of an antiemetic substance 15 to 
30 minutes prior to ingestion of glycerol 
was carried out in patients predisposed to 
vomiting. 
We have used all of the above proce-
dures, as well as iced tomato juice. Tri-
methobenzamide hydrochloride ( Tigan) 
administered by suppository or by mouth 
taken approximately 30 minutes earlier 
gives near-perfect relief, as does intra-
muscular prochlorperazine ( Compazine) 5 
to 10 mg., 30 minutes before glycerol ad-
ministration. 
Minor neurologic complaints such as 
headache and dizziness have been men-
tioned in some reports.11• 45 D'Alena and 
Ferguson20 reported 2 patients as having 
more serious side effects. An 82-year-old 
woman with hypertension was given one 
oral dose of 2 Gm. per kilogram, about 
twice the usual dose. Within several hours 
she developed a headache, nausea, and 
shaking of one arm. The patient was asymp-
tomatic in several days. A second patient 
with diabetes mellitus developed moderate 
diabetic acidosis 2 days after initiation of 
glycerol therapy. Within 24 hours after 
stopping glycerol and starting insulin, he 
was under control. It was unlikely that 
glycerol contributed directly to the prob-
lem in this patient. 
Human intravascular studies 
Bowesman10 is believed to have reported 
the first intravascular use of glycerol. He 
injected 2 to 3 mi. of 10 per cent glycerol 
into the femoral artery at weekly intervals 
for the control of leg edema secondary to 
elephantiasis. Patients were followed up to 
40 days with measurements of limb cir-
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cumference. Results were satisfactory and 
no ill effects were noted. 
Sloviter65 showed that a considerable 
quantity of glycerol in relatively dilute form 
could be given intravenously to human sub-
jects with no ill effects. His study was 
undertaken because of concern about the 
amount of glycerol which remained in the 
erythrocyte-glycerol mixture of stored red 
blood cells at the time of transfusion. Five 
per cent glycerol in isotonic saline was 
given intravenously for 3 to 6 hours to 
hospitalized patients. The largest amount 
given was 1.2 Gm. per kilogram. Monitoring 
heart rhythm and rate showed no change. 
No headache, visual symptoms, pain at the 
injection site, or venous thromboses oc-
curred. Plasma hemoglobin concentrations 
obtained up to 7 hours after infusion were 
not significantly different from preinfusion 
values. No hemoglobinuria was found, but 
there was a moderate diuresis. 
Intravenous infusion of sterile 30 per 
cent glycerol solutions in 10 per cent sugar 
or in 6 per cent dextran diluted in 0.9 per 
cent sodium chloride was used by Cantore 
and associates.15 When the solution was 
injected at a rate of 60 drops per minute 
( 0.8 to 1 Gm. per kilogram total dose), a 
marked reduction of increased intracranial 
pressure resulted, even in the most serious 
cases. However, intravenous administration 
was used only in a "limited" number of pa-
tients because of the "frequent" occurrence 
of "transient" hemoglobinuria. No data 
were presented. 
Wolf and associates85 studied elimination 
rates of glycerol in term and premature in-
fants by intravenous infusion of 0.1 Gm. of 
glycerol per kilogram in 5 minutes and 
found the highest elimination rate in pre-
mature newborn infants. Four-week-old in-
fants had rates nearly as high as did adults. 
Birth weights ranged from 3,000 to 4,190 
grams. No ill effects were reported. Havel27 
infused glycerol-2-H3 intravenously to 
young men before, during, and after exer-
cise to measure turnover rates. The dose of 
glycerol was not great. The highest plasma 
concentration attained was 0.154 ,u.moles 
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per milliliter ( 1.4 mg./100 ml.), and no 
ill effects were noted. Faster turnover 
occurred during exercise. Senior and Lori-
dan,60 using much higher doses of intra-
venous glycerol, studied 22 control sub-
jects, 4 patients with glucose-6-phosphate 
dehydrogenase (G-6-P-DH) deficiency, one 
patient deficient in amylo-1,6-glucosidase, 
and 2 patients deficient in phosphorylase. 
They infused 10 per cent glycerol in isotonic 
sodium chloride in a dose of 120 mmoles 
per square meter of body surface over a 
4 minute period. This is about 19 Gm. for 
a 70 Kg. man. The disposal rate was most 
rapid in the G-6-P-DH-deficient patients 
and faster than that of the control subjects 
for the other groups. Half life for glycerol 
in the control subjects was about 30 min-
utes. The highest blood level obtained was 
10 mmoles per liter. No toxic effects were 
reported. 
Several authors13• 56• 74• 75• 79 have de-
scribed the intravenous use of 30 per cent 
glycerol in 20 per cent sodium ascorbate 
for use in ocular and cerebral hypertension. 
The sodium ascorbate was added because 
in animal experiments it was shown to pre-
vent the hemoglobinuria and renal changes 
that result with intravenous glycerol. These 
authors used 0.6 Gm. per kilogram of glyc-
erol and 0.28 Gm. per kilogram of sodium 
ascorbate in a total volume of 140 mi. 
given over a 15 to 20 minute period. No 
hemolysis or hemoglobinuria was noted. 
Turnover and excretion 
Free glycerol is present in the plasma of 
rabbits, sheep, guinea pigs, rats, and man. 
In man, the concentration of plasma glyc-
erol is increased by norepinephrine and 
decreased by insulin.61 During states of 
mobilization such as starvation and hyper-
thyroidism, the plasma glycerol concentra-
tion may rise to 3 to 4 mg. per 100 ml,5 
Glycerol given to diabetic patients during 
partial insulin withdrawal leads to a de-
crease in ketones and in glycosuria, sug-
gesting that glycerol may be metabolized 
without the aid of insulin. 25 
Glycerol is removed from the body by the 
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liver ( 80 to 90 per cent) and the kidney 
( 10 to 20 per cent). 7 This would appear 
to be consistent with the observation of 
Wieland and Suyter82 of the distribution of 
glycerokinase. The distribution of glycerol 
is generally felt to correspond to the extra-
cellular space, 50 to 65 per cent of the 
body weight. 29 Exactly how quickly in-
travascular glycerol equilibrates with the 
tissue water is not precisely known, but it 
is probably within minutes during con-
tinuous intravenous infusion at a constant 
rate.83 
Renal excretion has been observed by 
Zilversmit and McCandless, 86 who reported 
that, when the plasma levels of glycerol 
reach 1 mg. per milliliter ( 1.1 mmoles per 
liter) or below, the amount of urinary glyc-
erol is "negligible." Kruhj1jffer and Nissen37 
have shown that essentially complete re-
absorption of glycerol occurs in cats at low 
filtered loads, but that more and more glyc-
erol appears in the urine as the plasma 
concentration increases. The reason for this 
is based on the assumption that "reabsorp-
tion" at low filtered loads is predominantly 
accounted for by metabolic conversion of 
glycerol by the tubular lumen cells to C02, 
glucose, and lactate. At higher plasma con-
centrations, the glycerol converting en-
zymes become saturated and glycerol spills 
into the urine. Swanson and Thompson, 69 
using stop-flow methods, found that glyc-
erol was completely reabsorbed when the 
plasma concentration was less than 15 mg. 
per 100 mi. ( 1.6 mmoles per liter) in the 
dog. For concentrations between 30 and 
200 mg. per 100 ml. ( 3.2 and 21.3 mmoles 
per liter), the fractional reabsorption tends 
to approach a roughly constant value de-
pending on the state of diuresis. 
The nonrenal (essentially hepatic) con-
tribution to glycerol turnover has been 
studied by Winkler and associates83 in the 
dog. They found that, over the physiologic 
range of glycerol concentrations (up to 0.5 
mmoles per liter), the relationship of the 
uptake to plasma concentration is de-
scribed by a simple regression line. At 
higher concentrations uptake departs from 
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linearity and simulates a saturation-type 
kinetic curve. Over a seventyfold range of 
plasma glycerol concentrations conformed 
to a specific equation describing a segment 
of a hyperbola. They also showed that, 
during constant intravenous infusion of 
glycerol, a steady state of plasma glycerol 
and tissue specific activity is achieved, so 
that glycerol uptake and input is simply the 
infusion rate divided by the plasma glyc-
erol specific activity. It was found in this 
study that asymptomatic values of plasma 
glycerol activity are reached in 20 to 30 
minutes with or without a priming dose. 
Also of interest is that glycerolkinase has 
been found in intestinal mucosa, 26 lymphatic 
tissue,36 lung,38 and pancreas.28 Whether 
glycerol is metabolized by all of these 
tissues is not known. 
Advantages of glycerol as an 
intracranial hypotensive agent 
For a long time we have needed a cere-
bral dehydration agent that can be used on 
a continuous basis. Steroids, although effec-
tive in cerebral edema, have a limitation 
by the nature of their well-known side 
effects, such as duodenal ulcer, psychoses, 
fluid retention, and predisposition of pa-
tient to infection. These effects would be 
particularly undesirable in patients with 
encephalitis or meningitis or in postopera-
tive patients. Furthermore, steroids are 
most effective in cerebral edema due to 
neoplasm and pseudotumor cerebri. 
Urea34• 54• 55 and mannitol4 cannot be 
used on a long-term basis because of the 
marked water and electrolyte washout as-
sociated with their use. Mannitol is not 
reabsorbed from the tubular lumen to any 
appreciable degree, therefore, a high per-
centage of the administered dose under-
goes renal excretion, causing very marked 
osmotic diuresis. 
Glycerol does not produce much water 
or electrolyte loss and does not depend 
solely on the kidney to reduce brain water/5 
although it gains access to renal tissue 
easily.19• 80 Glycerol has been reported ef-
fective in the nephrectomized animal, 15 
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which suggests it removes water from the 
brain by an extrarenal mechanism. Only 
100 mi. of brain water is necessary to in-
crease intracranial pressure profoundly.62 
Reed and Woodbury54• 55 measured the 
amount of water removed from the CNS 
of rats by the administration of urea. If 
their findings are applicable to man, then 
adequate reduction of CSF pressure re-
quires removal of about 100 mi. of water. 
This volume of water could easily be ac-
commodated by expansion of the systemic 
vascular compartment, without a need for 
diuresis. Urea regularly produces a rebound 
overshoot of intracranial pressure. The sec-
ond or slow ascent phase is felt to be due 
to urea entering or remaining in the brain 
cells after the extracellular urea level falls, 
and thereby water moves by osmosis into 
the brain producing an increase of intra-
cranial pressure. 
Waterhouse and Coxon,80 in a well-pre-
sented study, demonstrated the existence of 
an efficient CSF-brain barrier to glycerol 
by simultaneous perfusion of intravascular 
and ventricular systems with radioactive 
glycerol. Because glycerol does not enter 
the CNS, these results would indicate that 
rebound overshoot of CSF pressure would 
not be expected with glycerol. Whether or 
not glycerol is metabolized by brain tissue 
is currently disputed, 66• 80 but the point re-
mains that in the intact animal the intra-
cellular concentration has not been found 
to exceed the extracellular concentration.80 
In cases in which the blood-brain barrier 
is not intact, it is conceivable that the 
reverse may be true. 
Crone19 measured the arteriovenous dif-
ference of glycerol and found that glycerol 
disappeared no more readily than did Evans 
blue dye which does not pass the blood-
brain barrier. On the other hand, Sloviter 
and associates66 found normalization of ipsi-
lateral hemispheric electroencephalogram 
changes due to hypoglycemia (rabbits) 
when intracarotid glycerol was given; he 
suggested that glycerol passed the barrier 
and acted as a substrate for brain metab-
olism. 
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The nutrient value of glycerol ( 4.32 calo-
ries per gram) is of some importance, as it 
can supply a caloric yield greater than that 
supplied by an equal amount of glucose. 
One gram per kilogram given orally every 
6 hours to a 70 Kg. man would supply 
1,210 calories per 24 hours. 
Proposed use of intravenous glycerol 
for cerebral edema 
Based on this review of the world litera-
ture, it is our opinion that the intravenous 
administration of glycerol on a continuous 
basis has not been systematically studied 
as a means of controlling cerebral edema or 
CNS rehydration. We believe that on the 
basis of the evidence, serious consideration 
should be given to such therapy. It is ap-
parent that, when given in low concentra-
tions in the proper vehicle, glycerol does 
not produce hemolysis or renal lesions as 
was previously believed. It is anticipated 
that intravenous administration should 
eliminate nausea and vomiting; hence, it 
becomes a more suitable agent for use in 
coma with increased intracranial pressure 
and preoperative dehydration of the 
CNS. 
It is probable that the dosage of glycerol 
required to produce ocular dehydration is 
the same as that for cerebral dehydration. 76 
It has been shown45 that a fall in intra-
ocular pressure begins at plasma glycerol 
levels of approximately 10 mmoles per liter. 
Therefore, it is reasonable to devise an 
intravenous infusion scheme for cerebral 
dehydration which results in blood levels of 
10 mmoles per liter. 
To convert the oral dosage used by Mc-
Curdy and associates45 to an intravenous 
one is complex. For example, the intestines 
contain glycerolkinase, and the blood from 
the gut is carried to the liver which metab-
olizes about 80 per cent of the body's glyc-
erol. Therefore, the total oral dose is not 
distributed to the systemic extracellular 
water space ( CNS is not included) to 
which glycerol equilibrates. Since the half-
life of glycerol in man is about 30 minutes 
and the oral dose of glycerol lowers the 
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CSF pressure for 6 hours, it is again ob-
vious that the effective plasma concentra-
tion of glycerol is much less than the 
amount based on calculated total oral dose 
after a correction for metabolism and its 
solution in the total body water space. 
We have been able to make only specu-
lations based on the conversion of animal 
data to man. When glycerol was given in-
travenously to dogs, data have been re-
ported to be similar to those in man83 at 
the rate of 0.05 mmoles per minute per 
kilogram, for one to 2 hours-a plasma con-
centration of 2 mmoles per liter was ob-
tained and sustained. This turns out to be 
6.5 Gm. of glycerol per day per kilogram, 
similar to the oral dosage needed to pro-
duce cerebral dehydration. 
Is it possible that an intravenous route 
is less effective in maintaining a blood level 
of glycerol than is the oral one? Or is it 
possible that blood levels of glycerol in-
creased to 10 mmoles per liter, the mini-
mum value given for intraocular dehydra-
tion, will produce cerebral dehydration? 
Along this same line, Cantore and asso-
ciates15 infused intravenously 0.3 Gm. ( 3.3 
mmoles) of glycerol per minute, 1 Gm. ( 19 
mmoles) total dose. They said, "It always 
produced a marked antiedematous effect, 
even in the most serious cases." They gave 
no CSF pressure data in relationship to the 
initiation of glycerol therapy or glycerol 
blood levels. It is possible that plasma levels 
in the area of 10 mmoles per liter were 
reached. Of great importance is the report 
by Senior and Loridan. 60 They gave 19 Gm. 
of glycerol intravenously to a 70 Kg. man 
( 0.27 Gm. per kilogram) as a 10 per cent 
solution in isotonic saline in 4 minutes and 
obtained a maximum blood level of 10 
mmoles per liter, the minimum concentra-
tion reported by McCurdy and associates 45 
necessary to produce ocular dehydra-
tion. 
With the information at hand, we think 
it is possible to explore the possibilities of 
the safe administration of glycerol via the 
intravenous route on a continuous or semi-
continuous basis in man. 
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